Table 2.
Summary of sources cited.
| Authors [Ref] |
Title | Type of Study | Source of Data | Information about Publication |
|---|---|---|---|---|
| Promoted by Eli Lilly and Company [25] |
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis | Phase II RCT | clinicaltrials.gov NCT02576938 (accessed on 2 November 2021) |
Last update posted 17 June 2020 |
| Promoted by Eli Lilly and Company [26] |
A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (BREEZE-AD1) | Phase III RCT | clinicaltrials.gov NCT03334396 (accessed on 2 November 2021) |
Last update posted 18 August 2020 |
| Promoted by Eli Lilly and Company [27] |
Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (BREEZE-AD2) | Phase III RCT | clinicaltrials.gov NCT03334422 (accessed on 2 November 2021) |
Last update posted 22 January 2020 |
| Promoted by Eli Lilly and Company [28] |
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3) | Phase III RCT | clinicaltrials.gov NCT03334435 (accessed on 2 November 2021) |
No results posted |
| Promoted by Eli Lilly and Company [29] |
A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable (BREEZE-AD4) | Phase III RCT | clinicaltrials.gov NCT03428100 (accessed on 2 November 2021) |
Last update posted 11 May 2021 (pre-print) |
| Promoted by Eli Lilly and Company [30] |
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis (BREEZE-AD5) | Phase III RCT | clinicaltrials.gov NCT03435081 (accessed on 2 November 2021) |
Last update posted 19 August 2021 |
| Promoted by Eli Lilly and Company [31] |
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis (BREEZE-AD6) | Phase III RCT | clinicaltrials.gov NCT03559270 (accessed on 2 November 2021) |
No results posted |
| Promoted by Eli Lilly and Company [32] |
A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis (BREEZE-AD7) | Phase III RCT | clinicaltrials.gov NCT03733301 (accessed on 2 November 2021) |
Last update posted 11 August 2020 |
| Promoted by Eli Lilly and Company [33] |
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS) | Phase III RCT | clinicaltrials.gov NCT03952559 (accessed on 2 November 2021) |
No results posted |
| Guttman-Yassky et al. [34] |
Baricitinib in adult patients with moderate to severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. | PHASE II RCT | NCT02576938 | Published on 2019 J Am Acad Dermatol. |
| Simpson EL et al. [35] |
Baricitinib in patients with moderate to severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. | Phase III RCT |
BREEZE-AD1 NCT03334396 BREEZE-AD2 NCT03334422 |
Published on August 2020 Br J Dermatol. |
| Reich K. et al. [36] |
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. | Phase III RCT |
BREEZE-AD7 NCT03733301 |
Published on December 2020 JAMA Dermatol |
| Simpson EL et al. [37] |
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5) | Phase III RCT |
BREEZE-AD5 NCT03435081 |
Published on July 2021 J Am Acad Dermatol. |
| Reich K. et al. [38] |
Baricitinib improves symptoms in patients with moderate to severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials | Phase III RCT |
BREEZE-AD1 NCT03334396 BREEZE-AD2 NCT03334422 |
Published on November 2020 J Dermatolog Treat Epub ahead of print |
| Wollemberg A. et al. [39] |
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life, and functioning in adult patients with moderate to severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomised trial | Phase III RCT |
BREEZE-AD7 NCT03733301 |
Published on July 2021 J Eur Acad Dermatol Venereol. |
| Thyssen JP et al. [40] |
Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7 | Phase III RCTs |
BREEZE-AD1 NCT03334396 BREEZE-AD2 NCT03334422 BREEZE-AD7 NCT03733301 |
Published on October 2021 Dermatol Ther |
| Buhl T. [41] |
Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post-Hoc Analysis of 3 Phase 3 Studies. | Phase III RCTs |
BREEZE-AD1 NCT03334396 BREEZE-AD2 NCT03334422 BREEZE-AD7 NCT03733301 |
Published on June 2021 Dermatol Ther |
| King B. et al. [42] |
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials | Phase II–III RCTs |
NCT02576938 BREEZE-AD1 NCT03334396 BREEZE-AD 2 NCT03334422 BREEZE-AD3 NCT03334435 BREEZE-AD4 NCT03428100 BREEZE-AD5 NCT03435081 BREEZE-AD6 NCT03559270 BREEZE-AD7 NCT03733301 |
Published on May 2021 Am J Clin Dermatol |
| Bieber T. et al. [43] |
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. | Phase III RCTs |
BREEZE-AD1 NCT03334396 BREEZE-AD2 NCT03334422 BREEZE-AD3 NCT03334435 BREEZE-AD4 NCT03428100 BREEZE-AD5 NCT03435081 BREEZE-AD6 NCT03559270 BREEZE-AD7 NCT03733301 |
Published on February 2021 J Eur Acad Dermatol Venereol. |
Abbreviations: RCT, randomized controlled trials; ref: references.